Expired Canadian patentCanada
Endogenous growth hormone
CA 1313134 C · Owner: Eli Lilly And Company · Inventors: Wagner, Jack Frederick
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
X-6509, Abstract, The concentration of endogenous growth hormone in the bloodstream of an economic mammal is increased by the simultaneous administration of an estrogen and a growth hormone releasing factor.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted January 26, 1993. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended January 26, 2010.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledDecember 17, 1987
GrantedJanuary 26, 1993
Term endedJanuary 26, 2010
Patent numberCA 1313134 C
Classification (IPC)A61K38/25
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.